Kualitas bukti 4.5/5
Skor tinjauan delapan dimensi terhadap rubrik kualitas . Setiap dimensi dinilai 1–5.
- D1 Dasar sumber
- 4/5
- D2 Otoritas sumber
- 5/5
- D3 Aritmetika
- 5/5
- D4 Ketidakpastian
- 4/5
- D5 Cakupan
- 4/5
- D6 Prosa
- 5/5
- D7 Kejujuran persepsi
- 4/5
- D8 Kelengkapan peringatan
- 5/5
● faktor Anda — klik risiko ini ▾ untuk menampilkan
- Faktor Anda
≈ Sama mungkinnya dengan
Dipersepsikan
Penyakit kardiovaskular secara luas dipahami sebagai penyebab kematian utama pada perempuan di seluruh dunia, tetapi peran spesifik menopause sebagai pemercepat risiko tidak dipahami dengan baik oleh sebagian besar perempuan. Perhatian budaya terhadap kanker payudara — hasil yang secara statistik lebih jarang — telah menggeser kesadaran akan profil risiko kardiovaskular yang diubah oleh menopause. Perempuan di akhir usia 40-an dan awal 50-an sering tidak tahu bahwa risiko penyakit kardiovaskular mereka berlipat ganda dalam dekade setelah menstruasi terakhir mereka, atau bahwa transisi ini merupakan jendela yang berarti untuk intervensi pencegahan. Asimetri ini diperkuat oleh praktik klinis: konsultasi menopause secara historis berfokus pada penanganan gejala (vasomotor, tidur, genitourinari) alih-alih stratifikasi risiko kardiovaskular.
Sumber: intuisi redaksi, bukan hasil survei
Aktual
33 dari 100 perempuan di seluruh dunia akan mengalami penyakit kardiovaskular selama hidup mereka (sejak usia 40 tahun)
perempuan sejak usia 40 tahun (risiko PJK seumur hidup, Framingham / Lloyd-Jones 1999; pengubah waktu menopause dari IPD gabungan Lancet Public Health 2019 dan dokumen konsensus EHJ 2021)
Tampilkan perhitungan
Angka native (33/100 ≈ 1 dari 3) adalah risiko penyakit jantung koroner seumur hidup sejak usia 40 tahun yang dilaporkan oleh Lloyd-Jones dkk. (Lancet 1999, Framingham): 31,7 % (95 % CI 29,2–34,2) untuk perempuan. Inilah angka yang memunculkan judul familiar «satu dari tiga perempuan». Waktu menopause mengubah baseline ini: analisis IPD gabungan Lancet Public Health 2019 (15 studi, 301.438 perempuan) menemukan menopause dini (<40) membawa hazard ratio 1,55 (95 % CI 1,38–1,73) untuk penyakit kardiovaskular non-fatal pertama versus menopause pada usia 50–51, naik menjadi 1,88 sebelum usia 60. Dokumen konsensus EHJ 2021 menambahkan peningkatan ~3 % risiko kardiovaskular per tahun menopause yang lebih dini dan mencatat bahwa kenaikan risiko kardiovaskular terkait menopause tidak dapat dipisahkan secara bersih dari penuaan kronologis — sehingga entri ini memperlakukan menopause sebagai pengubah risiko yang bergantung pada waktu, bukan penggandaan yang sepenuhnya independen dari penuaan. Angka seumur hidup 1-dari-3 berasal dari AS/Framingham khusus untuk PJK; payung «penyakit kardiovaskular» yang lebih luas serta estimasi global/regional bervariasi, yang tercermin dalam rentang ketidakpastian dan caveat. Rendah (0,28): CI bawah / profil faktor risiko dan regional yang menguntungkan (mis. perempuan Asia Timur dengan beban kardiovaskular lebih rendah). Tinggi (0,40): profil beban lebih tinggi (mis. perempuan Eropa Timur / Asia Tengah dengan prevalensi hipertensi dan merokok tinggi, serta hitungan seluruh-CVD yang lebih luas alih-alih hanya PJK).
Catatan: Judul «1 dari 3 sejak usia 40 tahun» adalah risiko penyakit jantung koroner seum…
Judul «1 dari 3 sejak usia 40 tahun» adalah risiko penyakit jantung koroner seumur hidup secara khusus, dari kohort Framingham (Lloyd-Jones 1999, 31,7 % untuk perempuan); angka ini berasal dari AS dan khusus PJK, bukan angka seluruh-CVD global, sehingga estimasi global dan regional berbeda. Payung «penyakit kardiovaskular» yang lebih luas (menambahkan stroke, penyakit arteri perifer, dan gagal jantung) serta hitungan hanya-PJK-fatal memberikan angka berbeda. Risiko waktu menopause adalah peningkatan risiko relatif, bukan insidensi absolut: dalam data gabungan Lancet PH 2019, menopause dini (<40) membawa HR 1,55 untuk kejadian kardiovaskular non-fatal pertama (1,88 sebelum usia 60), dan konsensus EHJ 2021 melaporkan tambahan ~3 % risiko kardiovaskular per tahun menopause yang lebih dini — tetapi konsensus yang sama menegaskan kenaikan terkait menopause tidak dapat dipisahkan secara bersih dari penuaan kronologis, sehingga «percepatan» ini tidak boleh dibaca sebagai penggandaan yang sepenuhnya independen dari penuaan. Jika risiko PJK absolut seorang perempuan di usia 40-an rendah, peningkatan relatif tetap membiarkan tingkat absolutnya rendah. Bukti jendela-peluang MHT relevan secara klinis tetapi tidak tertanam dalam probabilitas native; itu termasuk dalam diskusi klinis, bukan baseline populasi. Variasi regional substansial — perempuan Jepang dan Korea memiliki risiko kardiovaskular seumur hidup lebih rendah dan perempuan Eropa Timur / Asia Tengah lebih tinggi — mencerminkan profil hipertensi dan merokok yang berbeda, yang didekati oleh rentang ketidakpastian.
Risiko terkait
Risiko lain dengan tema serupa — untuk menjelajahi ketakutan terkait.
Serangan jantung pertama
Berapa peluang mengalami serangan jantung pertama sebelum usia 70 tahun?
Pengalaman menjanda
Seberapa mungkin saya hidup lebih lama dari pasangan dan menjadi janda atau duda?
Gangguan penggunaan alkohol
Berapa peluang mengembangkan gangguan penggunaan alkohol seumur hidup?
Risiko AUD warisan
Jika orang tua memiliki gangguan penggunaan alkohol, berapa kemungkinan Anda mengembangkan gangguan penggunaan alkohol sendiri?
Kehilangan pekerjaan & depresi
Berapa kemungkinan mengembangkan depresi setelah kehilangan pekerjaan?
Pilih penantang
Cardiovascular disease is the leading cause of death in women globally, and in the US it kills more women each year than all cancers combined — yet the specific role of menopause as a risk accelerant is poorly understood by most women and inconsistently addressed in clinical practice. The Framingham Heart Study’s lifetime-risk analysis (Lloyd-Jones et al., Lancet 1999) put the lifetime risk of coronary heart disease from age 40 at 31.7% for women — about one in three. Menopause timing modifies that baseline: a 2019 Lancet Public Health pooled analysis of 15 studies covering 301,438 women found that women with premature menopause (before age 40) had a hazard ratio of 1.55 (95% CI 1.38–1.73) for a first non-fatal cardiovascular event compared with menopause at 50–51, with the excess larger before age 60 (HR 1.88). A European consensus document (Maas et al., European Heart Journal 2021) reports a roughly 3% rise in CVD risk per year of earlier menopause, while cautioning that the menopause-related increase in cardiovascular risk cannot be cleanly separated from chronological ageing.
The mechanism is estrogen-related. Estrogen has direct beneficial effects on vascular endothelium: it promotes vasodilation, reduces LDL cholesterol, and suppresses inflammatory markers. As estrogen levels decline through perimenopause and fall sharply after the final menstrual period, these protective effects diminish. The result is a measurable shift in vascular risk profile that occurs over a 5–10 year window around menopause, leaving a woman’s cardiovascular risk trajectory substantially steeper than it would have been had estrogen remained at premenopausal levels. The timing of menopause modifies the magnitude: in the Lancet Public Health pooled data, women who experienced premature menopause (before 40) carried roughly 1.5 times the cardiovascular-event risk of women with menopause at 50–51 overall, and close to 1.9 times before age 60 — and the European consensus document notes that women with premature ovarian insufficiency have a shorter life expectancy from cardiovascular disease and osteoporosis.
The clinical evidence on menopausal hormone therapy (MHT) adds an important nuance: a window-of-opportunity effect has been described. The European Heart Journal consensus document reports that “early initiation of MHT after menopause has the greatest benefit for cardiovascular health” and that women starting MHT below age 60 or within 10 years of menopause onset showed a significant reduction (>30%) in myocardial infarction or cardiac deaths. The earlier era of cardiovascular MHT concerns derived primarily from the Women’s Health Initiative, which enrolled older postmenopausal women initiating therapy more than a decade after menopause. The menopause-CVD relationship is therefore not only about risk magnitude but also about timing of intervention — a distinction that matters practically for how women and their clinicians approach the transition.
Fakta terkait
Sekitar 1 dari 3 wanita di dunia mengalami penyakit kardiovaskular seumur hidupnya, dan kejadian penyakit jantung koroner hampir berlipat ganda pada dekade setelah menopause. Kanker payudara lebih menarik perhatian, tetapi penyakit jantung membunuh jauh lebih banyak wanita.
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
3/4 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
-
[1] European Heart Journal (European Society of Cardiology) — Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists Terverifikasi
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists- Statistik
Each year of early menopause is associated with a ~3% increased risk of CVD; women with premature ovarian insufficiency have shorter life expectancy due to CVD; the CVD-risk increase at menopause cannot be cleanly distinguished from ageing; MHT initiated below age 60 or within 10 years of menopause onset was associated with a >30% reduction in MI or cardiac deaths (window-of-opportunity effect)- Kutipan
“"Each year of early menopause was associated with a 3% increased risk of CVD. Women with premature ovarian insufficiency (POI), defined as the loss of ovarian function before the age of 40, have a shorter life expectancy than women with a late menopause due to CVD and osteoporosis. While CVD risk increases with the menopause, this cannot be distinguished from ageing. Lower oestrogen levels after menopause are related to altered vascular function, enhanced inflammation, and up-regulation of other hormonal systems." "Women initiating MHT treatment below 60 years of age or within 10 years of onset of menopause showed a significant reduction (>30%) of MI or cardiac deaths." ”
- Data sumber dari
- 2021-03-07
- Diakses
- 2026-06-30
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- Maas et al. (2021), European Heart Journal 42(10):967–984 — a consensus document from European cardiologists, gynaecologists, and endocrinologists (formally approved by the ESC Clinical Practice Guidelines Committee, but not the 2021 ESC CVD-prevention guideline itself). Used here for the menopause-specific risk modifiers: the 3%-per-year early-menopause gradient, premature ovarian insufficiency, and the estrogen-vascular mechanism. The same document also describes a menopausal-hormone-therapy (MHT) "window of opportunity": women initiating MHT below age 60 or within 10 years of menopause onset showed a significant (>30%) reduction in MI or cardiac deaths, which anchors the MHT paragraph in the body text. Note the document explicitly cautions that the menopause-associated CVD-risk rise cannot be cleanly separated from chronological ageing — the entry reflects this caveat rather than claiming a fully aging-independent effect.
-
[2] The Lancet Public Health — Age at natural menopause and risk of cardiovascular disease: pooled individual participant data from 15 observational studies
Age at natural menopause and risk of cardiovascular disease: pooled individual participant data from 15 observational studies- Statistik
Premature menopause (<40) associated with HR 1.55 (95% CI 1.38–1.73) for first non-fatal CVD vs menopause at 50–51; the excess is larger before age 60 (HR 1.88, 1.62–2.20). Pooled IPD, 301,438 women, 15 studies.- Kutipan
“"Compared with women who had menopause at age 50-51 years, the risk of cardiovascular disease was higher in women who had premature menopause (age <40 years; HR 1·55, 95% CI 1·38-1·73; p<0·0001), early menopause (age 40-44 years; 1·30, 1·22-1·39; p<0·0001), and relatively early menopause (age 45-49 years; 1·12, 1·07-1·18; p<0·0001). The associations persisted in never smokers, and were strongest before age 60 years for women with premature menopause (HR 1·88, 1·62-2·20; p<0·0001) and early menopause (1·40, 1·27-1·54; p<0·0001), but were attenuated at age 60-69 years, with no significant association observed at age 70 years and older." ”
- Data sumber dari
- 2019-11-01
- Diakses
- 2026-06-30 · salinan arsip
- Perhitungan
- Zhu et al. (2019) Lancet Public Health — pooled IPD, 15 studies, 301,438 women (12,962 first non-fatal CVD events; 9,369 CHD; 4,338 stroke). The largest individual-participant dataset quantifying the menopause-timing–CVD relationship. The reported risk is for first non-fatal cardiovascular disease (a composite), not a separate CHD hazard ratio; premature menopause (<40) carries HR 1·55 overall and 1·88 before age 60. These figures support the `personal_factor_multipliers` for premature/surgical menopause used in this entry.
-
[3] The Lancet — Lifetime risk of developing coronary heart disease Terverifikasi
Lifetime risk of developing coronary heart diseaseSee all 2 Likelier entries citing this source →
- Statistik
Lifetime risk of coronary heart disease at age 40 is 31.7% (95% CI 29.2–34.2) for women and 48.6% for men — i.e. about one in three women. Framingham Heart Study, 7,733 participants.- Kutipan
“"Lifetime risk of CHD after 40 years of age was 48·6% (95% CI 45·8–51·3) for men and 31·7% (29·2–34·2) for women. At 70 years of age the remaining lifetime risk was 34·9% for men and 24·2% for women. Interpretation: Lifetime risk at age 40 years is one in two for men and one in three for women." ”
- Data sumber dari
- 1999-01-09
- Diakses
- 2026-06-30 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- Lloyd-Jones, Larson, Beiser & Levy (1999), Lancet 353(9147):89–92 — Framingham Heart Study lifetime-risk analysis (n=7,733, CHD-free at baseline). This is the original source of the "one in three women from age 40" lifetime coronary-heart-disease figure that anchors this entry's native rate. Note the headline figure is for coronary heart disease specifically (not the full CVD umbrella) and is US/Framingham-derived; the entry's caveats flag that broader-CVD and global figures differ.
-
[4] American Heart Association / Go Red for Women — The Facts about Women and Heart Disease Terverifikasi
The Facts about Women and Heart Disease- Statistik
Cardiovascular disease kills more US women each year than all forms of cancer combined; only 44% of women recognize CVD as their greatest health threat- Kutipan
“"Cardiovascular disease kills more women than all forms of cancer combined and yet only 44% of women recognize that cardiovascular disease is their greatest health threat." ”
- Data sumber dari
- 2024-01-01
- Diakses
- 2026-07-03 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- American Heart Association's Go Red for Women campaign facts page. Used here to source the entry's opening framing claim that cardiovascular disease kills more US women annually than all cancers combined, which motivates the "underrated" myth framing alongside the menopause-specific timing evidence from Maas et al. and Zhu et al. This is an all-cause CVD statistic, not menopause-specific.
- Independensi
- Independent of the Framingham (Lloyd-Jones 1999), Lancet Public Health (Zhu 2019), and EHJ consensus (Maas 2021) sources — an AHA public-health communications source used solely for the all-cause CVD-vs-cancer mortality comparison in US women, not for any menopause-timing figure.